Blood Alterations Preceding Clinical Manifestation of Glioblastoma

Background: There is little knowledge on blood alterations of glioblastoma. We had the opportunity to investigate markers from plasma taken 66, 36, and 6 months before glioblastoma in a patient in the VITA study. Methods: We determined S100B, secretagogin, neuropeptide-Y, micro-RNA-21, let-7, micro-RNA-128, andmicro-RNA-342-3p in our patient and 10 controls from VITA. Results: We found a four-fold increase of micro-RNA-21 in the plasma of glioblastoma patient, whereas controls showed a significant decrease. There was no difference in other protein or micro-RNA levels between the patient and controls. Conclusion: Plasma micro-RNA-21 may be associated with glioblastoma development in individual cases.